Therefore, there has been increasing interest in identifying bioactive compounds that have potential for reducing triglyceride, non-HDL cholesterol, GPT and GOT and also enhancing adiponectin levels to help manage obesity and its associated metabolic diseases. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.